Search Results

New formulation expands Sanofi’s Sarclisa portfolio by offering a subcutaneous delivery option across multiple myeloma treatment settings, including newly diagnosed, relapsed and refractory disease. The US Food and Drug Administration (FDA) has approved a subcutaneous formulation of isatuximab-irfc (Sarclisa Escena) for the treatment of adults with multiple myeloma across three approved treatment combinations. The approval provides patients and healthcare professionals with an alternative administration method to the existing intravenous formulation of the Sanofi-developed anti-CD38 monoclonal antibody. The FDA decision was supported by clinical data demonstrating that subcutaneous isatuximab-irfc delivered comparable efficacy to intravenous administration, while offering the potential for a more convenient treatment experience through reduced administration burden. Subcutaneous Sarclisa Matches Intravenous Efficacy in Phase III Study The primary evidence supporting the FDA approval came from the Phase III IRAKLIA trial (NCT05405166), which evaluated whether subcutaneous administration could provide similar outcomes to the existing intravenous formulation. The open-label, randomised non-inferiority study enrolled 531 patients with multiple myeloma, assigning participants to receive either subcutaneous isatuximab-irfc with an on-body delivery system or intravenous isatuximab-irfc, both alongside pomalidomide and dexamethasone. The study met its key objectives: Overall response rate (ORR) was 71.1% in the subcutaneous treatment group compared with 70.5% in the intravenous group. Drug exposure levels were comparable, with steady-state trough concentrations favouring subcutaneous administration. The results demonstrated that subcutaneous Sarclisa maintained the clinical activity of intravenous therapy while providing an alternative delivery option for patients. Additional Clinical Data Support Broader Multiple Myeloma Use The FDA approval was also supported by data from additional clinical studies evaluating subcutaneous isatuximab-irfc in different multiple myeloma populations. In the Phase II IZALCO study (NCT05704049), subcutaneous Sarclisa was evaluated in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. The study reported: Overall response rate of 79.7% based on independent review committee assessment. The Phase II IsaSocut study (NCT05889221) evaluated subcutaneous isatuximab-irfc alongside bortezomib, lenalidomide and dexamethasone in newly diagnosed multiple myeloma patients who were not eligible for stem cell transplantation. The study demonstrated: Overall response rate of 97.3%. Together, these results supported the use of subcutaneous Sarclisa across multiple stages of multiple myeloma treatment. Addressing Treatment Burden in Multiple Myeloma Care Multiple myeloma remains a complex blood cancer requiring long-term treatment approaches involving combinations of targeted therapies, immunomodulatory drugs and corticosteroids. While anti-CD38 antibodies such as isatuximab-irfc have become important components of multiple myeloma treatment, intravenous administration can increase clinic time and place additional demands on healthcare systems. The introduction of a subcutaneous formulation could help simplify treatment delivery by providing a potentially faster and more flexible administration approach. The move also reflects a wider trend across oncology, where pharmaceutical companies are increasingly developing subcutaneous versions of established biologic therapies to improve patient convenience and optimise healthcare resource use. Sarclisa Safety Profile Remains Consistent The FDA prescribing information includes warnings and precautions relating to: Hypersensitivity and administration-related reactions Neutropenia Infections Secondary primary malignancies Laboratory test interference Embryo-fetal toxicity Healthcare professionals are advised to monitor patients for potential adverse reactions during treatment. What the FDA Approval Means for Multiple Myeloma Treatment The approval of subcutaneous Sarclisa expands treatment options for patients with multiple myeloma by providing an alternative to intravenous administration without compromising clinical efficacy. With positive results from the Phase III IRAKLIA study and supporting Phase II data across multiple treatment settings, Sanofi’s Sarclisa portfolio is positioned to play a broader role in the evolving multiple myeloma treatment landscape. As oncology care continues to move towards more convenient and patient-centred delivery models, subcutaneous biologics are expected to become an increasingly important part of long-term cancer management. Summary The FDA has approved subcutaneous isatuximab-irfc (Sarclisa Escena) for adults with multiple myeloma across newly diagnosed, relapsed and refractory treatment settings. The approval was supported by the Phase III IRAKLIA trial, which showed comparable efficacy between subcutaneous and intravenous administration, alongside additional Phase II studies demonstrating strong response rates in different patient populations. The new formulation expands Sanofi’s multiple myeloma offering while supporting a broader shift towards more convenient cancer treatment delivery. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The ALARION-EV trial will evaluate AtaCor Medical’s investigational parasternal extravascular implantable cardioverter-defibrillator (EV-ICD) system, designed to provide an alternative approach to traditional ICD therapy for patients at risk of life-threatening arrhythmias. AtaCor Medical has enrolled the first patient in its pivotal ALARION-EV clinical trial evaluating its investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system, marking a key milestone in the development of next-generation cardiac rhythm management technology. The multicentre study will assess the safety and effectiveness of AtaCor’s EV-ICD system in patients who require defibrillation therapy but do not need chronic pacing support for slow heart rhythms. The trial represents an important step towards expanding ICD treatment options by evaluating a system designed to avoid placement of leads inside the heart and blood vessels. What Is AtaCor’s Extravascular ICD System? Traditional implantable cardioverter-defibrillators (ICDs) use leads positioned inside the heart to detect abnormal rhythms and deliver electrical shocks when required. AtaCor’s EV-ICD approach uses an extravascular design, meaning the system is implanted outside the heart and vascular system. The investigational system combines: AtaCor’s Atala lead, implanted through a small left parasternal incision with electrodes positioned against the pericardium. Abbott’s pulse generator, positioned in either a lateral or pectoral device pocket. The company believes this approach could provide an alternative option for patients requiring defibrillation therapy while reducing some limitations associated with traditional transvenous ICD systems. ALARION-EV Pivotal Trial Design The prospective, multicentre, single-arm ALARION-EV study will enrol approximately 280 patients across up to 40 clinical sites in the United States and the Netherlands. The trial is designed for patients who require ICD therapy but do not require chronic pacing for bradycardia. Researchers will evaluate the safety and effectiveness of the investigational parasternal EV-ICD system through at least six months of follow-up. Data generated from the study are expected to support a future Premarket Approval (PMA) submission to the US Food and Drug Administration (FDA). Advancing Next-Generation Cardiac Rhythm Management AtaCor Medical said the first patient treatment represents a significant milestone in its efforts to develop new approaches to cardiac rhythm management. Rick Sanghera, CEO of AtaCor Medical, said the achievement reflected the company’s commitment to advancing extravascular therapies designed to improve patient outcomes. The AtaCor-Abbott EV-ICD system remains investigational and has not received regulatory approval or commercial availability. Growing Interest in Implantable Cardiac Devices The development of alternative ICD technologies comes as demand for advanced cardiac rhythm management solutions continues to grow. Implantable cardioverter-defibrillators remain a critical therapy for preventing sudden cardiac death in patients at risk of dangerous ventricular arrhythmias. However, innovation in the field is increasingly focused on improving implantation techniques, reducing procedural complexity and developing technologies that minimise reliance on traditional transvenous approaches. Why the ALARION-EV Trial Matters Successful results from the ALARION-EV study could support the development of a new category of extravascular ICD technology. By evaluating whether an EV-ICD system can provide effective defibrillation therapy without traditional intracardiac leads, AtaCor aims to address ongoing challenges within cardiac rhythm management and expand treatment options for patients requiring implantable defibrillator therapy. Summary AtaCor Medical has enrolled the first patient in its ALARION-EV pivotal clinical trial evaluating an investigational extravascular implantable cardioverter-defibrillator (EV-ICD) system. The study will assess the safety and effectiveness of AtaCor’s parasternal EV-ICD technology, which combines the company’s Atala lead with Abbott’s pulse generator. If successful, the trial could support regulatory submission and advance the development of next-generation cardiac rhythm management solutions. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The agreement gives AstraZeneca exclusive rights to develop, manufacture and commercialise TQC3721 outside China, expanding the company’s respiratory pipeline with an investigational PDE3/4 inhibitor targeting chronic respiratory diseases including chronic obstructive pulmonary disease (COPD). AstraZeneca and Sino Biopharmaceutical subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have entered into an exclusive licensing agreement for TQC3721, an inhaled phosphodiesterase 3/4 (PDE3/4) inhibitor currently in clinical development for respiratory diseases. Under the agreement, AstraZeneca will gain rights to develop, manufacture and commercialise TQC3721 outside China, while also securing exclusive global rights to certain future development programmes. Sino Biopharmaceutical will receive an upfront payment of $200 million from AstraZeneca, with additional development, regulatory and commercial milestones potentially increasing the total value of the collaboration to $1.9 billion. The deal also includes tiered royalties on annual net sales, which could reach double-digit percentages for TQC3721 products. AstraZeneca Expands Respiratory Pipeline With PDE3/4 Inhibitor TQC3721 is an inhaled PDE3/4 inhibitor designed to deliver both bronchodilator and anti-inflammatory effects by targeting two pathways involved in respiratory disease. Sino Biopharmaceutical is developing the therapy for chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD), where persistent airway inflammation and reduced lung function remain significant treatment challenges. The company believes dual inhibition of PDE3 and PDE4 could provide complementary benefits by improving lung function, reducing exacerbations and addressing broader disease burden compared with therapies targeting individual pathways. The programme is being developed in two formulations: Nebulised TQC3721, currently being evaluated in a Phase III clinical trial in China. Dry powder inhaler formulation, currently being assessed in a Phase II study. Phase IIb COPD Data Support Further Development Early clinical data have strengthened interest in TQC3721 as a potential next-generation respiratory therapy. In a Phase IIb study evaluating the nebulised formulation in patients with COPD, Sino Biopharmaceutical reported that TQC3721 demonstrated a potential best-in-class profile. The positive findings supported progression into late-stage development, with the Phase III trial designed to further evaluate the therapy’s safety and efficacy in COPD patients. If successful, TQC3721 could provide an additional treatment option in a respiratory market where companies continue to seek therapies capable of improving symptom control, reducing exacerbations and supporting long-term disease management. Strategic Importance for AstraZeneca’s Respiratory Portfolio The collaboration reinforces AstraZeneca’s continued focus on respiratory medicine, an area where the company has established a strong global presence through therapies for asthma and COPD. By gaining access to TQC3721, AstraZeneca adds an investigational inhaled therapy with a differentiated mechanism of action to its pipeline. The agreement combines Sino Biopharmaceutical’s discovery capabilities and clinical development progress in China with AstraZeneca’s global expertise in respiratory medicine and commercialisation infrastructure. Sino Biopharmaceutical said the partnership will help accelerate the global development of TQC3721 and maximise its potential clinical and commercial value. Growing Momentum Behind China Pharma Partnerships The AstraZeneca-Sino Biopharmaceutical agreement reflects the growing role of Chinese biotechnology and pharmaceutical companies in global licensing activity. For Sino Biopharmaceutical, the deal represents its second major out-licensing transaction with a multinational pharmaceutical company in 2026. Earlier this year, the company entered into a separate collaboration with Sanofi involving the experimental oral JAK/ROCK inhibitor rovadicitinib. AstraZeneca has also continued to expand its presence in China through strategic partnerships, including collaborations focused on innovative drug discovery platforms and emerging therapeutic areas. Why the TQC3721 Deal Matters The agreement highlights continued investment in next-generation respiratory medicines as pharmaceutical companies look beyond established COPD treatments. For AstraZeneca, TQC3721 provides access to a late-stage respiratory asset with potential applications in a large and growing patient population. For Sino Biopharmaceutical, the partnership provides global development expertise and commercial reach needed to advance its respiratory innovation beyond China. A successful clinical programme could position TQC3721 as a potential differentiated treatment option for COPD and other chronic respiratory diseases. Summary AstraZeneca has signed an exclusive licensing agreement with Sino Biopharmaceutical subsidiary CTTQ for TQC3721, an inhaled PDE3/4 inhibitor being developed for chronic respiratory diseases including COPD. The deal includes a $200 million upfront payment and could generate up to $1.9 billion in milestone payments, alongside tiered royalties. Currently in Phase III development in China, TQC3721 represents AstraZeneca’s latest move to strengthen its respiratory pipeline through strategic partnerships and emerging global innovation. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The FDA has approved Sarclisa Escena, a subcutaneous on-body injector formulation of Sanofi’s multiple myeloma therapy isatuximab, becoming the first cancer treatment authorised in the US for delivery through an on-body injector system. Sanofi has secured US Food and Drug Administration (FDA) approval for Sarclisa Escena, a new subcutaneous (SC) formulation of its multiple myeloma therapy Sarclisa (isatuximab-irfc) delivered through an on-body injector (OBI). The approval represents a milestone in oncology drug delivery, as Sarclisa Escena becomes the first cancer therapy approved in the US that can be administered using an on-body injector alongside manual subcutaneous injection. Sarclisa Escena is approved across all existing US indications for the intravenous (IV) formulation of Sarclisa in multiple myeloma, providing healthcare professionals and patients with an additional treatment administration option. New Sarclisa Formulation Expands Multiple Myeloma Treatment Options Multiple myeloma is a blood cancer caused by the abnormal growth of plasma cells in the bone marrow, leading to complications including bone damage, anaemia, kidney problems and weakened immune function. Sarclisa is a monoclonal antibody targeting CD38, a protein expressed on multiple myeloma cells. By binding to CD38, the therapy helps activate immune mechanisms that attack and eliminate cancer cells. The newly approved Sarclisa Escena formulation allows the medicine to be delivered subcutaneously through either: The CirCLIQ on-body injector (OBI), providing automated hands-free administration. Manual subcutaneous injection, offering additional flexibility for healthcare providers. The approval covers Sarclisa’s existing US indications, including use in combination treatment regimens for patients with relapsed or refractory multiple myeloma and newly diagnosed disease. Phase III IRAKLIA Trial Supports FDA Approval The FDA approval was supported by clinical data from multiple studies, including the Phase III IRAKLIA non-inferiority trial. The study compared Sarclisa Escena delivered through the CirCLIQ on-body injector with the existing intravenous formulation in patients with multiple myeloma. In IRAKLIA, patients receiving Sarclisa Escena alongside pomalidomide and dexamethasone achieved an objective response rate (ORR) of 71.1%. This compared with an ORR of 70.5% among patients receiving the intravenous Sarclisa formulation with the same treatment combination. The trial demonstrated that the subcutaneous on-body injector formulation achieved comparable: Efficacy outcomes Pharmacokinetic exposure Overall safety profile compared with the established IV formulation. On-Body Injector Technology Reduces Treatment Burden The CirCLIQ on-body injector was developed using Enable Injections’ enFuse platform, a technology designed to simplify the administration of large-volume injectable medicines. The wearable device uses a retractable 30-gauge needle and is designed to automatically deliver the medicine without requiring healthcare professionals to manually administer prolonged injections. Sanofi said the system aims to reduce the physical effort associated with delivering high-resistance injections while allowing healthcare professionals to spend more time monitoring patients during treatment. The technology could help improve the treatment experience for patients receiving long-term cancer therapies by reducing administration complexity and shortening time spent in clinical settings. Sarclisa Escena Demonstrates Comparable Safety Profile Safety findings from the IRAKLIA trial were consistent with the known safety profile of intravenous Sarclisa. However, the subcutaneous on-body injector formulation demonstrated a reduction in systemic administration-related reactions. Systemic administration reactions occurred in: 1.5% of patients receiving Sarclisa Escena 25% of patients receiving intravenous Sarclisa The results suggest that the new delivery method may provide a more convenient administration approach without compromising the established clinical profile of the therapy. Impact on the Future of Oncology Drug Delivery The FDA approval of Sarclisa Escena reflects a wider shift towards improving convenience and reducing treatment burden in oncology. As more cancer therapies move beyond traditional intravenous infusion models, pharmaceutical companies are increasingly exploring alternative delivery technologies that can support outpatient treatment, improve patient experience and optimise healthcare resources. Sanofi’s approval of Sarclisa Escena positions the company at the forefront of this movement, introducing the first FDA-approved oncology treatment delivered through an on-body injector. Why This Approval Matters The approval of Sarclisa Escena provides patients with multiple myeloma and healthcare providers with a new way to administer an established therapy. By combining comparable efficacy and safety with a potentially simpler delivery method, the treatment could help reduce the burden associated with long-term cancer care. The decision also highlights the growing importance of drug delivery innovation alongside advances in oncology therapeutics, as companies seek to make complex treatments more accessible and patient-friendly. Summary Sanofi has received FDA approval for Sarclisa Escena, a subcutaneous on-body injector formulation of its multiple myeloma therapy isatuximab. Supported by Phase III IRAKLIA data, the therapy demonstrated comparable efficacy and safety to intravenous Sarclisa while significantly reducing administration-related reactions and treatment complexity. The approval marks the first FDA-approved oncology drug delivered through an on-body injector and represents a significant advance in the evolution of cancer treatment delivery. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

Germany’s healthcare system overhaul introduces billions in savings measures while increasing pressure on pharmaceutical companies. German lawmakers have approved a major healthcare cost-reduction package aimed at addressing the country’s growing budget pressures, introducing measures that will significantly increase financial contributions from the pharmaceutical industry. The reforms, approved by Germany’s federal and state governments, are designed to reduce healthcare spending by €16.3 billion ($18.6 billion) as the country faces a projected budget shortfall of more than €40 billion ($45.8 billion) by 2030. While the measures are intended to improve the sustainability of Germany’s statutory health insurance system, they have faced strong opposition from pharmaceutical companies, with several major drugmakers warning that the changes could affect future investment in the country. Germany Healthcare Reform Targets Pharmaceutical Spending A central part of the legislation is a significant increase in mandatory pharmaceutical rebates paid by drug manufacturers. The reforms will: Increase the legally required pharmaceutical rebate from 7% to 15.5% Introduce an additional 9% rebate on patented vaccines Freeze vaccine prices until 2030 Limit hospital cost increases until 2029 Increase healthcare co-payments for some services According to the German Bundestag, the pharmaceutical rebate increase is intended to ensure that the industry makes a direct contribution towards controlling healthcare expenditure. The final legislation represents a compromise compared with earlier proposals that would have introduced a dynamic rebate system linked to overall pharmaceutical spending and healthcare system revenues. Drugmakers had criticised the original approach, arguing that variable rebates would make financial planning and investment decisions more difficult. Government Says Reform Is Necessary to Control Healthcare Costs German Health Minister Nina Warken said the reforms were necessary given the scale of the country’s financial challenge. “With necessary savings of almost €19 billion in the coming year alone, it is clear that there will be noticeable changes and that this law will demand something from everyone,” Warken said. The German government argues that the measures are required to protect the long-term sustainability of the statutory health insurance system, which provides coverage for the majority of the country’s population. However, pharmaceutical companies have warned that increased cost pressures could impact research investment, manufacturing expansion and the availability of innovative medicines. Pharmaceutical Industry Pushes Back Against German Healthcare Changes The reforms have received strong criticism from pharmaceutical leaders, who argue that Germany risks becoming a less attractive location for investment. Several major pharmaceutical companies raised concerns after the healthcare overhaul was initially proposed earlier in 2026. Pfizer Raises Investment Concerns Pfizer CEO Albert Bourla warned German Chancellor Friedrich Merz that the reforms could damage Germany’s attractiveness as a destination for pharmaceutical investment. Bourla also withdrew from an international investor conference in Germany following the announcement of the proposals. Roche Reviews Future Investment Plans Roche Pharma CEO Daniel Steiners also said the company would reassess future investment decisions in Germany due to concerns over the changing healthcare environment. Eli Lilly Reduces Manufacturing Investment Eli Lilly reduced its planned investment in a manufacturing facility in Rhineland-Palatinate. The company cut the planned spending on the site, which was intended to support production of its weight-loss medicines, from approximately €2.3 billion ($2.7 billion). Boehringer Ingelheim Scales Back Spending German pharmaceutical company Boehringer Ingelheim also reduced planned investment in its domestic operations, cancelling more than €900 million ($1 billion) in planned expenditure. US Government Reviews German Drug Pricing Policies The healthcare reforms have also attracted attention beyond Germany. The US government launched an investigation into Germany’s pharmaceutical pricing policies, examining whether what it described as persistent underpayment for innovative medicines could represent an unreasonable or discriminatory burden on US pharmaceutical companies. The review reflects broader international tensions around medicine pricing, with governments attempting to control healthcare costs while pharmaceutical companies argue that lower reimbursement can affect innovation and investment. What Germany’s Healthcare Reform Means for Pharma Germany remains one of the world’s largest pharmaceutical markets, but the latest reforms highlight the growing challenge facing healthcare systems globally: balancing affordability with continued investment in innovation. For pharmaceutical companies, the increased rebate requirements represent a direct reduction in potential revenue from the German market. The industry will now be closely monitoring whether the reforms influence: future research and development investment manufacturing expansion decisions clinical trial activity availability of newly launched medicines While Germany’s government views the changes as necessary cost controls, pharmaceutical companies argue that maintaining investment incentives will be critical to ensuring continued access to innovative therapies. Summary Germany has approved a major healthcare cost-saving package designed to reduce spending by €16.3 billion, including a significant increase in pharmaceutical rebates and new pricing restrictions. The reforms increase the pharmaceutical rebate rate from 7% to 15.5% and introduce additional measures targeting healthcare expenditure. While policymakers argue the changes are needed to strengthen the country’s healthcare system, major pharmaceutical companies including Pfizer, Roche, Eli Lilly and Boehringer Ingelheim have warned that the reforms could impact future investment decisions in Germany. The legislation highlights the ongoing global debate between healthcare affordability and maintaining incentives for pharmaceutical innovation. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much do cardiologists make in 2026? Cardiologists remain among the highest-compensated physician specialists in the United States, with new data from the AMGA 2026 Medical Group Compensation and Productivity Survey showing continued growth in cardiology compensation. For general non-invasive cardiologists, median compensation reached $648,852 in 2026, representing a 5.4% increase year-over-year. At the same time, cardiology productivity increased more modestly, with median work relative value units (wRVUs) rising 1.5% to 9,415. For cardiologists evaluating employment contracts, negotiating compensation packages or benchmarking career progression, understanding how salary growth compares with productivity expectations provides valuable insight into current market conditions. Key Findings: Cardiologist Compensation in 2026 According to the AMGA 2026 Medical Group Compensation and Productivity Survey: Median cardiologist compensation: $648,852 Year-over-year salary growth: +5.4% Median work RVUs: 9,415 Year-over-year wRVU growth: +1.5% Compensation per wRVU: $68.79 Compensation per wRVU growth: +2.9% The latest benchmarks suggest cardiology compensation growth is currently outpacing productivity growth, highlighting continued demand for cardiovascular specialists. Cardiologist Salary in 2026: Compensation Increased 5.4% The AMGA survey shows median compensation for general non-invasive cardiologists increased from: Year Median Compensation 2025 $615,621 2026 $648,852 This represents: +$33,231 increase year-over-year 5.4% compensation growth For practicing cardiologists, this provides a useful benchmark when assessing whether current compensation remains aligned with national market trends. For physicians negotiating new employment agreements, compensation benchmarks can help evaluate: base salary offers productivity incentives annual increases retention packages Cardiology Productivity Trends: Are wRVUs Increasing? Salary growth is only one part of physician compensation. Many cardiology contracts remain closely linked to productivity metrics, particularly work relative value units (wRVUs), which measure clinical activity and physician output. The AMGA data shows: Metric 2025 2026 Change Median wRVUs 9,274 9,415 +1.5% The increase indicates that cardiologists generated slightly higher clinical productivity in 2026. However, productivity growth was significantly lower than compensation growth, suggesting that higher earnings were not solely driven by increased workload. Potential factors influencing compensation growth include: continued demand for cardiovascular specialists physician recruitment challenges workforce shortages adjustments to physician compensation models Cardiology Compensation Per wRVU: What Does It Mean? The compensation-to-wRVU ratio shows how much physicians receive for each unit of productivity generated. For general non-invasive cardiology: Year Compensation per wRVU 2025 $66.80 2026 $68.79 This represents: 2.9% growth year-over-year A higher compensation-per-wRVU ratio may indicate that employers are increasing financial incentives to attract and retain cardiologists. For physicians, this metric can be particularly useful when reviewing productivity-based compensation plans. A contract may appear competitive based on total salary, but the underlying relationship between compensation and expected wRVUs determines whether the workload expectations are realistic. Why Cardiologists Should Pay Attention to Compensation Benchmarks Compensation data provides more than a salary comparison. For cardiologists, market benchmarks can support important career decisions. Contract Negotiations National compensation data can help physicians understand whether an offer is competitive. Key areas to evaluate include: guaranteed compensation wRVU thresholds bonus structures compensation per wRVU rates partnership opportunities Career Planning Cardiology remains one of the most financially attractive physician specialties. Benchmarking can help physicians compare opportunities across: hospital employment private practice academic medicine health system positions Understanding market rates can also support career decisions around location, subspecialisation and employment models. Productivity Expectations Compensation models increasingly connect physician earnings with measurable productivity. Tracking changes in: wRVUs compensation per wRVU salary growth can help cardiologists understand whether increased clinical expectations are being appropriately recognised . Cardiology Compensation Outlook: Demand Remains Strong Demand for cardiovascular specialists continues to grow as healthcare systems manage ageing populations and increasing rates of cardiovascular disease. At the same time, healthcare organisations face ongoing financial pressures, reimbursement challenges and physician workforce shortages. This creates a competitive environment for cardiology talent. The latest AMGA data suggests that employers are continuing to increase compensation to attract and retain cardiologists, even as productivity growth remains relatively modest. Summary: Cardiologist Salary Trends in 2026 The AMGA 2026 Medical Group Compensation and Productivity Survey shows continued growth in cardiologist compensation. General non-invasive cardiologists recorded: Median compensation of $648,852 5.4% year-over-year salary growth 9,415 median wRVUs $68.79 compensation per wRVU While productivity increased by 1.5%, compensation growth was stronger, suggesting that market demand and physician recruitment pressures are contributing factors in rising cardiology salaries. For cardiologists reviewing contracts, evaluating career opportunities or benchmarking their current compensation, AMGA data provides an important reference point for understanding the 2026 physician compensation landscape. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are physicians earning in 2026? Physician compensation continued to rise in 2026, with new data from the AMGA 2026 Medical Group Compensation and Productivity Survey showing that healthcare providers experienced further growth in both compensation and productivity. The latest survey found that overall clinical compensation increased 4.3% year-over-year, while median work relative value units (wRVUs) increased by 2.4%. The data provides insight into how physician salaries are changing across major categories, including: primary care physicians medical specialists surgical specialists radiology, anesthesiology and pathology advanced practice clinicians (APCs) For physicians reviewing employment contracts, negotiating compensation packages or benchmarking career progression, understanding the relationship between salary growth and productivity expectations is becoming increasingly important. Key Findings: Physician Compensation Trends in 2026 According to the AMGA 2026 Medical Group Compensation and Productivity Survey: Overall physician compensation growth: +4.3% Overall wRVU growth: +2.4% Primary care compensation growth: +3.7% Medical specialty compensation growth: +4.3% Surgical specialty compensation growth: +3.2% Radiology/anesthesiology/pathology compensation growth: +5.7% APC compensation growth: +4.1% The survey reflects compensation and productivity data from 451 medical groups and health systems representing nearly 188,000 providers across more than 190 specialties. The overall picture suggests that physician compensation continues to increase, although the pace of growth varies significantly depending on specialty. Physician Salary Growth in 2026: Compensation Increased Across Every Major Category The AMGA data shows continued salary growth across all major physician groups. Specialty Category Compensation Growth 2026 Overall +4.3% Primary Care +3.7% Medical Specialties +4.3% Surgical Specialties +3.2% Radiology/Anesthesiology/Pathology +5.7% APCs +4.1% Among physician groups, radiology, anesthesiology and pathology recorded the strongest compensation growth at 5.7%, while surgical specialties saw the lowest increase at 3.2%. For physicians, this highlights that compensation trends are not moving uniformly across healthcare. Factors influencing salary growth may include: physician shortages specialty-specific demand recruitment pressures changing compensation models healthcare organisations competing for experienced providers Physician Productivity Trends: Are Doctors Working More for Higher Pay? Compensation growth does not tell the complete story. Many physician employment agreements link earnings to productivity metrics, particularly work relative value units (wRVUs). The AMGA survey shows: Category wRVU Growth 2026 Overall +2.4% Primary Care +2.0% Medical Specialties +2.0% Surgical Specialties +2.4% Radiology/Anesthesiology/Pathology +3.1% APCs +3.0% Overall physician productivity increased by 2.4%, slightly below compensation growth of 4.3%. This suggests that salary increases are not being driven purely by physicians generating higher clinical volume. Instead, compensation growth may also reflect: market competition for physicians efforts to improve retention adjustments to fair market value benchmarks increased demand for specialist care What Does Compensation Per wRVU Mean for Physicians? One of the most important metrics in physician compensation models is the relationship between pay and productivity. The compensation-per-wRVU ratio helps show how much physicians are being paid for each unit of clinical production. A higher ratio can indicate that physicians are receiving greater financial recognition for their productivity. For physicians reviewing employment agreements, this metric can help answer important questions: Is my productivity target realistic? Does my compensation reflect my workload? How does my contract compare with market benchmarks? Compensation structures vary significantly by specialty, which is why specialty-specific benchmarks are essential. For example, a cardiologist, gastroenterologist and orthopedic surgeon may all have different productivity expectations and compensation-per-wRVU levels. Why Physicians Should Pay Attention to Compensation Benchmarks Salary data is not just about comparing earnings. For physicians, compensation benchmarks can influence major career decisions. Contract Negotiations Market data can help physicians evaluate: base salary offers productivity incentives bonus structures wRVU thresholds annual compensation reviews Understanding national benchmarks provides a stronger position when negotiating employment agreements. Career Planning Physician compensation varies considerably depending on specialty. The AMGA data highlights why doctors should compare their own specialty rather than relying on overall physician averages. Career decisions around: specialty choice practice setting hospital employment private practice opportunities can all be influenced by compensation trends. Productivity Expectations Many modern physician contracts combine guaranteed compensation with productivity incentives. Understanding changes in: salary growth wRVUs compensation-per-wRVU helps physicians determine whether additional workload is being appropriately rewarded. Which Physician Specialties Saw the Biggest Salary Increases in 2026? The largest compensation increase among major physician categories came from: Radiology, Anesthesiology and Pathology +5.7% This was followed by: Medical Specialties +4.3% Primary Care +3.7% Surgical Specialties +3.2% Within individual specialties, compensation trends varied further. Examples include: General non-invasive cardiology: $648,852 (+5.4%) Gastroenterology: $656,500 (+3.6%) Hematology and medical oncology: $591,080 (+6.2%) Orthopedic surgery: $751,350 (+0.3%) These differences demonstrate why specialty-level compensation benchmarking is more valuable than looking only at overall physician averages. The Outlook for Physician Compensation in 2026 Physician compensation continues to be shaped by a complex healthcare environment. Medical groups and health systems are balancing: rising demand for healthcare services physician workforce shortages reimbursement pressures changing care delivery models increased use of advanced practice clinicians The latest AMGA data suggests that physicians continue to see compensation growth, but the relationship between pay, productivity and specialty demand remains highly individual. For doctors, understanding specialty-specific market benchmarks will become increasingly important when evaluating career opportunities. Summary: Physician Salary Trends in 2026 The AMGA 2026 Medical Group Compensation and Productivity Survey shows continued growth in physician compensation across the US healthcare system. Key findings include: Overall physician compensation increased 4.3% wRVUs increased 2.4% Medical specialties increased 4.3% Primary care increased 3.7% Surgical specialties increased 3.2% While physician salaries continue to rise, compensation growth varies significantly by specialty. For physicians evaluating contracts, planning career moves or benchmarking their current earnings, understanding salary trends and productivity expectations provides valuable insight into the changing healthcare employment market. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are gastroenterologists earning in 2026? Gastroenterologists remain among the highest-compensated medical specialists in the United States, with the latest AMGA 2026 Medical Group Compensation and Productivity Survey showing continued growth in physician earnings alongside modest increases in clinical productivity. For gastroenterologists evaluating employment contracts, negotiating compensation packages or benchmarking their current position against national market data, understanding the relationship between salary growth, workload and productivity is essential. The latest AMGA data shows that median compensation for gastroenterologists reached $656,500 in 2026, representing a 3.6% increase year-over-year. At the same time, productivity growth was more limited, with median work relative value units (wRVUs) increasing by 0.5%, suggesting compensation growth has exceeded changes in measured clinical output. For physicians, this distinction matters. A rising salary does not necessarily mean a corresponding increase in workload — and compensation benchmarks can provide valuable leverage during contract discussions. How Much Do Gastroenterologists Earn in 2026? According to the AMGA 2026 Medical Group Compensation and Productivity Survey, median compensation for gastroenterologists increased from: Year Median Compensation 2025 $633,422 2026 $656,500 This represents an annual increase of: +$23,078 or: 3.6% growth year-over-year Gastroenterology continues to rank among the highest-paid medical specialties, reflecting the complexity of digestive disease management, demand for procedural expertise and the financial contribution generated through diagnostic and therapeutic procedures. For gastroenterologists reviewing employment agreements, this benchmark provides a reference point when assessing whether base salary, incentive structures and productivity expectations align with current market conditions. Gastroenterologist Productivity Trends: Are wRVUs Increasing? Compensation alone does not provide the complete picture. Many gastroenterology employment models are influenced by productivity measures, particularly work RVUs, which are designed to reflect physician workload and clinical activity. The AMGA survey shows: Metric 2025 2026 Change Median wRVUs 9,008 9,052 +0.5% The increase indicates that gastroenterologists generated slightly higher levels of measured productivity compared with the previous year. However, compensation growth was significantly higher than wRVU growth, meaning the market value of gastroenterology services increased faster than reported productivity levels. This may reflect several factors, including: Continued demand for digestive disease specialists Pressure to recruit and retain gastroenterologists The value of procedural expertise within health systems Competition for experienced physicians in high-demand specialties What Does Compensation Per wRVU Mean for Gastroenterologists? The compensation-to-wRVU ratio provides another important benchmark by showing how much compensation physicians receive for each unit of productivity. For gastroenterology: Year Compensation per wRVU 2025 $70.47 2026 $72.28 This represents: 2.6% increase year-over-year A rising compensation per wRVU ratio suggests gastroenterologists are receiving greater financial recognition relative to productivity output. For physicians negotiating contracts, this figure can be particularly important when reviewing: Productivity incentive formulas Bonus thresholds Conversion rates Fair market value assessments A contract offering a lower compensation-per-wRVU rate may place greater pressure on physicians to generate higher volumes to achieve comparable earnings. Why Gastroenterologists Should Pay Attention to Compensation Trends Contract negotiations National compensation benchmarks provide gastroenterologists with evidence when reviewing employment offers, renewals or productivity-based compensation models. Key questions include: Is the guaranteed salary competitive? Are productivity targets achievable? Is the wRVU conversion rate aligned with market benchmarks? Are incentives rewarding additional clinical activity? Career planning Compensation data can help gastroenterologists evaluate career opportunities across different practice models, including: Hospital-employed positions Private practice groups Academic medicine Partnership opportunities Understanding market trends can help physicians assess whether a proposed role reflects current specialty demand. Understanding productivity expectations Gastroenterology is a specialty where compensation is often closely linked to procedural volume. Monitoring changes in: Compensation wRVUs Compensation per wRVU helps physicians understand whether income growth is being driven by: Increased workload Higher market demand Improved reimbursement structures Changes in compensation methodology The Bigger Picture for Gastroenterology Demand for gastroenterology services continues to increase as healthcare systems manage growing rates of digestive diseases, colorectal cancer screening requirements and chronic gastrointestinal conditions. At the same time, medical groups face pressure from reimbursement changes, workforce shortages and rising operational costs. For gastroenterologists, compensation data provides insight into how healthcare organisations are responding to these competing pressures. The latest AMGA figures suggest the specialty remains highly valued, with compensation increasing faster than productivity growth. Summary The AMGA 2026 Medical Group Compensation and Productivity Survey shows that gastroenterologists remain among the highest-compensated physician specialists in the United States. Key findings include: Median gastroenterologist compensation reached $656,500 in 2026 Compensation increased 3.6% year-over-year Median wRVUs increased 0.5% to 9,052 Compensation per wRVU increased 2.6% to $72.28 For gastroenterologists assessing employment contracts, negotiating compensation packages or benchmarking their careers, these figures provide a data-driven view of where the specialty stands in the current physician market. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are orthopedic surgeons earning in 2026? Orthopedic surgeons remain among the highest-compensated physician specialties in the US, with the latest AMGA 2026 Medical Group Compensation and Productivity Survey showing that orthopedic surgery compensation has remained stable despite continued growth in clinical productivity. For orthopedic surgeons reviewing employment contracts, negotiating compensation packages or benchmarking career progression, understanding how salary compares with workload expectations is essential. The latest AMGA data shows that median compensation for orthopedic surgeons reached $751,350 in 2026, making orthopedics one of the highest-paid surgical specialties tracked in the survey. However, compensation growth was modest compared with other physician specialties, increasing by just 0.3% year-over-year, while productivity increased slightly through growth in median work relative value units (wRVUs). How Much Do Orthopedic Surgeons Earn in 2026? According to the AMGA 2026 Medical Group Compensation and Productivity Survey, median compensation for orthopedic surgeons increased from: Year Median Compensation 2025 $748,799 2026 $751,350 This represents: +$2,551 increase year-over-year 0.3% compensation growth While compensation growth was relatively flat, orthopedic surgery remains one of the most financially rewarding physician specialties in the US healthcare market. For orthopedic surgeons evaluating current contracts, this benchmark provides insight into whether their compensation remains competitive relative to national employment trends. Orthopedic Surgeon Productivity Trends: Are wRVUs Increasing? Compensation alone does not show the full picture. Many orthopedic surgeon contracts are closely linked to productivity measures, particularly work relative value units (wRVUs), which are commonly used to measure clinical output. The AMGA survey shows: Metric 2025 2026 Change Median wRVUs 9,915 10,007 +0.9% The increase suggests orthopedic surgeons continued to generate slightly higher levels of clinical productivity year-over-year. However, productivity growth outpaced compensation growth, indicating that increased clinical output was not matched by a similar increase in overall compensation. For physicians working under productivity-based contracts, this distinction is particularly important when assessing whether additional workload is translating into increased earnings. What Does Compensation Per wRVU Mean for Orthopedic Surgeons? The compensation-to-wRVU ratio helps show how much physicians are being paid for each unit of productivity generated. For orthopedic surgery: Year Compensation per wRVU 2025 $78.00 2026 $78.94 This represents: 1.2% increase year-over-year A rising compensation-to-wRVU ratio can indicate changes in market demand, adjustments in physician employment models or increased competition for specialist talent. For orthopedic surgeons negotiating contracts, this metric can provide additional context beyond headline salary figures. Why Orthopedic Surgeons Should Pay Attention to Compensation Trends Compensation benchmarks can support several important career decisions. Contract negotiations National benchmarks provide orthopedic surgeons with data when reviewing: Base salary offers Productivity incentives wRVU thresholds Bonus structures Contract renewals Understanding where compensation sits relative to national averages can help physicians assess whether their current agreement reflects market conditions. Career planning Orthopedic surgeons considering different employment models can use compensation data to understand earning potential across: Hospital employment Health system roles Private practice opportunities New physician recruitment offers Productivity expectations Changes in wRVUs highlight whether compensation increases are being driven by: Increased clinical volume Greater procedural activity Market adjustments Changes in reimbursement structures For orthopedic surgeons, productivity remains a major component of financial performance. The Bigger Picture for Orthopedic Surgery Orthopedic care continues to experience strong demand driven by an ageing population, rising rates of musculoskeletal conditions and increasing demand for joint replacement procedures. At the same time, healthcare organisations are balancing specialist recruitment needs with broader financial pressures, reimbursement changes and changing physician employment models. The latest AMGA data suggests that orthopedic surgery remains one of the most highly valued medical specialties, although compensation growth has slowed compared with previous years. For orthopedic surgeons, understanding salary benchmarks, productivity expectations and compensation-per-wRVU trends provides important insight when evaluating career opportunities and negotiating future agreements. Summary The AMGA 2026 Medical Group Compensation and Productivity Survey shows that orthopedic surgeons remain among the highest-compensated physician groups in the US. Key findings include: Median orthopedic surgeon compensation: $751,350 Year-over-year compensation growth: 0.3% Median wRVUs: 10,007 wRVU growth: 0.9% Compensation per wRVU: $78.94 For orthopedic surgeons assessing contracts, employment opportunities or long-term career positioning, these benchmarks provide valuable insight into the current physician compensation landscape. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are nurse practitioners earning in 2026? Nurse practitioners (NPs) continue to play an increasingly important role in US healthcare, with new data from the AMGA 2026 Medical Group Compensation and Productivity Survey showing continued growth in both compensation and clinical productivity across multiple practice settings. As healthcare organisations expand their use of advanced practice clinicians (APCs) to improve patient access and address physician shortages, compensation benchmarking has become increasingly important for nurse practitioners evaluating job offers, negotiating contracts and planning their careers. The latest AMGA data shows that salary growth varied across NP specialties, with surgical specialty nurse practitioners recording the strongest year-over-year compensation increase, while primary care and medical specialty NPs also saw healthy gains. Productivity, measured by work relative value units (wRVUs), generally increased more slowly than compensation, suggesting employers continue to place a premium on attracting and retaining experienced nurse practitioners. Key Findings: Nurse Practitioner Compensation in 2026 According to the AMGA 2026 Medical Group Compensation and Productivity Survey: Specialty Median Compensation Salary Growth Primary Care NP $149,178 +4.8% Medical Specialty NP $147,269 +4.1% Surgical Specialty NP $149,614 +7.3% Additional benchmarks include: Primary Care NP wRVU growth: +2.4% Medical Specialty NP wRVU growth: +1.2% Surgical Specialty NP wRVU growth: -0.1% The survey reflects compensation data from nearly 188,000 providers across 451 medical groups and health systems, making it one of the largest physician and APC compensation benchmarking studies in the United States. Nurse Practitioner Salary by Specialty The AMGA data highlights relatively consistent salary levels across the three major NP practice settings, although salary growth differed significantly. Nurse Practitioner Specialty 2025 2026 Annual Change Medical Specialty $141,408 $147,269 +4.1% Primary Care $142,324 $149,178 +4.8% Surgical Specialty $139,411 $149,614 +7.3% The strongest increase came in surgical specialty nurse practitioners, where median compensation rose by more than $10,000 in a single year. For nurse practitioners comparing employment opportunities, these figures demonstrate how compensation can vary depending on clinical specialty rather than simply the NP role itself. Nurse Practitioner Productivity Trends: Are wRVUs Increasing? Many healthcare employers now combine guaranteed salaries with productivity-based incentives. The AMGA survey reports the following productivity changes: Specialty 2025 wRVUs 2026 wRVUs Change Medical Specialty NP 2,644 2,676 +1.2% Primary Care NP 4,539 4,647 +2.4% Surgical Specialty NP 2,179 2,177 -0.1% The data suggests compensation generally increased faster than productivity. For surgical specialty nurse practitioners in particular, salaries increased substantially despite productivity remaining virtually unchanged. This may reflect: Growing demand for experienced nurse practitioners Workforce shortages across specialist services Increased reliance on APC-led care models Competition between healthcare organisations to recruit experienced clinicians What Does Compensation Per wRVU Mean for Nurse Practitioners? Compensation per wRVU measures how much clinicians are paid for each unit of clinical productivity. The AMGA data shows: Specialty 2025 2026 Change Medical Specialty NP $53.09 $54.82 +3.3% Primary Care NP $32.19 $33.83 +5.1% Surgical Specialty NP $64.16 $67.17 +4.7% A higher compensation-per-wRVU ratio may indicate stronger market demand or improved compensation structures rather than simply increased workloads. For nurse practitioners reviewing employment agreements, this metric can help evaluate: Productivity bonus formulas Incentive thresholds Fair market compensation Expected clinical workload Why Nurse Practitioners Should Pay Attention to Compensation Benchmarks Compensation benchmarking is becoming increasingly valuable as nurse practitioner roles continue to evolve across the healthcare system. Contract negotiations Current market data provides valuable context when reviewing: Base salary Productivity incentives Annual pay reviews Bonus opportunities Employment offers Having access to national benchmarks can strengthen negotiations and help identify whether compensation is competitive within a particular specialty. Career planning Salary growth varies across NP specialties. Understanding market trends can help nurse practitioners evaluate opportunities in: Primary care Medical specialties Surgical services Hospital employment Large health systems Specialty choice may have a significant impact on long-term earning potential. Understanding productivity expectations Many healthcare organisations increasingly measure APC performance using productivity metrics. Monitoring changes in: Salary growth wRVUs Compensation per wRVU can help nurse practitioners determine whether increasing clinical expectations are being matched by appropriate financial rewards. The Outlook for Nurse Practitioner Compensation Demand for nurse practitioners continues to grow as healthcare systems seek to expand access to care while managing physician workforce shortages. Advanced practice clinicians are becoming an increasingly important component of care delivery across primary care, specialty medicine and surgical services. The latest AMGA data suggests employers continue to invest in attracting and retaining experienced nurse practitioners, with compensation growth generally exceeding productivity growth across most NP specialties. Summary The AMGA 2026 Medical Group Compensation and Productivity Survey shows continued growth in nurse practitioner compensation across the United States. Key findings include: Primary Care NP median salary: $149,178 (+4.8%) Medical Specialty NP median salary: $147,269 (+4.1%) Surgical Specialty NP median salary: $149,614 (+7.3%) While productivity increased modestly across most specialties, compensation generally rose at a faster pace, reflecting continued demand for nurse practitioners across the US healthcare system. For nurse practitioners evaluating employment opportunities, negotiating compensation or benchmarking career progression, these figures provide an important snapshot of the current APC employment market. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

How much are physician assistants earning in 2026? Physician assistants (PAs) continue to play an expanding role across the US healthcare system, with new data from the AMGA 2026 Medical Group Compensation and Productivity Survey highlighting how compensation varies by specialty while demand for experienced advanced practice clinicians (APCs) remains strong. As hospitals, physician groups and health systems increasingly rely on physician assistants to improve patient access and support multidisciplinary care, understanding salary benchmarks has become increasingly valuable for professionals reviewing employment contracts, negotiating compensation or planning their next career move. The latest AMGA data shows that surgical physician assistants remain the highest-paid PA specialty, while compensation growth differs considerably between primary care, medical specialties and surgical practice. Key Findings: Physician Assistant Compensation in 2026 According to the AMGA 2026 Medical Group Compensation and Productivity Survey: Specialty Median Compensation Salary Growth Physician Assistant – Primary Care $156,894 +1.3% Physician Assistant – Medical Specialty $146,873 -1.0% Physician Assistant – Surgical $159,659 +6.2% Additional benchmarks include: Primary Care PA wRVU change: -1.8% Medical Specialty PA wRVU growth: +2.6% Surgical PA wRVU growth: +3.8% The AMGA survey includes compensation data from 451 medical groups and health systems representing nearly 188,000 providers, making it one of the largest compensation benchmarking resources for physicians and APCs in the United States. Physician Assistant Salary by Specialty Compensation differs noticeably depending on clinical setting. Physician Assistant Specialty 2025 2026 Annual Change Medical Specialty $148,429 $146,873 -1.0% Primary Care $154,818 $156,894 +1.3% Surgical $150,326 $159,659 +6.2% The strongest salary growth occurred among surgical physician assistants, whose median compensation increased by more than $9,300 over the previous year. Meanwhile, physician assistants working in medical specialties experienced a modest decline in median compensation despite increases in productivity, highlighting how compensation trends can differ significantly across specialties. For physician assistants evaluating new opportunities, this reinforces the importance of comparing salaries within their own specialty rather than relying on overall APC averages. Physician Assistant Productivity Trends: Are wRVUs Increasing? Many physician assistant compensation models now include productivity incentives linked to work relative value units (wRVUs). The AMGA survey reports the following productivity changes: Specialty 2025 wRVUs 2026 wRVUs Change Medical Specialty PA 2,808 2,881 +2.6% Primary Care PA 4,959 4,868 -1.8% Surgical PA 1,760 1,827 +3.8% The data highlights several different trends across specialties. Medical specialty physician assistants generated higher productivity despite a slight reduction in compensation. Primary care physician assistants experienced declines in measured productivity while compensation still increased modestly. Surgical physician assistants saw both compensation and productivity increase, reflecting continued demand within surgical services. These differences demonstrate that salary growth is influenced by more than productivity alone, with recruitment pressures, workforce shortages and regional demand all likely contributing factors. What Does Compensation Per wRVU Mean for Physician Assistants? Compensation per wRVU measures how much clinicians are paid for each unit of productivity generated. The AMGA data shows: Specialty 2025 2026 Change Medical Specialty PA $52.54 $53.06 +1.0% Primary Care PA $31.83 $34.00 +6.8% Surgical PA $85.65 $85.35 -0.4% The compensation-per-wRVU ratio can provide valuable insight when reviewing productivity-based employment contracts. For example: Primary care physician assistants saw the largest increase in compensation per wRVU despite lower productivity. Surgical physician assistants maintained the highest compensation per wRVU overall, although the ratio declined slightly year-over-year. Medical specialty physician assistants recorded modest growth in compensation per unit of productivity. Understanding this metric can help physician assistants assess whether productivity expectations are appropriately rewarded. Why Physician Assistants Should Pay Attention to Compensation Benchmarks Compensation benchmarking is increasingly important as physician assistant roles continue to expand across healthcare. Contract negotiations National salary data can support discussions around: Base salary Productivity incentives Annual pay reviews Bonus opportunities Employment offers Benchmarking against national compensation figures provides useful context when reviewing contracts. Career planning Compensation varies considerably depending on specialty. Understanding current market trends can help physician assistants compare opportunities across: Primary care Medical specialties Surgical practice Hospital systems Multi-specialty physician groups Specialty selection may have a significant influence on long-term earning potential. Understanding productivity expectations As more employers incorporate productivity-based compensation models, physician assistants should monitor trends in: Salary growth wRVUs Compensation per wRVU These benchmarks help determine whether increasing workloads are translating into higher earnings. The Outlook for Physician Assistant Compensation Healthcare organisations continue to expand the use of physician assistants to improve access to care and support growing patient demand. As workforce shortages affect many physician specialties, experienced physician assistants are becoming increasingly valuable across primary care, specialist medicine and surgical services. The latest AMGA data shows that while compensation trends vary by specialty, physician assistants continue to see competitive salaries, particularly within surgical practice. Summary The AMGA 2026 Medical Group Compensation and Productivity Survey highlights continued demand for physician assistants across the US healthcare system. Key findings include: Primary Care PA median salary: $156,894 (+1.3%) Medical Specialty PA median salary: $146,873 (-1.0%) Surgical PA median salary: $159,659 (+6.2%) While productivity trends differed across specialties, compensation remained strongest in surgical practice, reinforcing the importance of specialty-specific benchmarking. For physician assistants reviewing contracts, negotiating salaries or planning career progression, these benchmarks provide a valuable snapshot of today's APC employment market. Source AMGA 2026 Medical Group Compensation and Productivity Survey. Data reflects 2025 compensation reported by participating medical groups and health systems. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com

The approvals expand the use of Keytruda and Keytruda Qlex alongside Padcev into the perioperative treatment setting for adults with muscle-invasive bladder cancer, regardless of cisplatin eligibility. The US Food and Drug Administration (FDA) has approved two new combinations from Merck & Co. (MSD) for the treatment of adults with muscle-invasive bladder cancer (MIBC), expanding the role of its immunotherapy platform Keytruda (pembrolizumab). The approvals cover: Keytruda (pembrolizumab) plus Padcev (enfortumab vedotin-ejfv) Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) plus Padcev Both combinations are approved for use in the neoadjuvant setting before surgery and adjuvant setting after surgery for patients with MIBC, including those who are not eligible for cisplatin-based chemotherapy. The FDA decision was supported by results from the Phase III KEYNOTE-B15 trial, also known as EV-304, which evaluated pembrolizumab and enfortumab vedotin-ejfv compared with standard neoadjuvant chemotherapy followed by surgery. The approval further strengthens MSD’s oncology portfolio, with Keytruda already one of the most widely used cancer immunotherapies globally. Phase III KEYNOTE-B15 Trial Shows Reduced Risk of Disease Events The KEYNOTE-B15 study enrolled 808 patients with muscle-invasive bladder cancer and assessed whether the combination of pembrolizumab and enfortumab vedotin-ejfv could improve outcomes compared with chemotherapy followed by surgery. In patients eligible for cisplatin-based chemotherapy, the Keytruda and Padcev combination demonstrated a: 47% reduction in the risk of event-free survival (EFS) events 35% reduction in the risk of death Median event-free survival was not reached among patients receiving pembrolizumab plus enfortumab vedotin-ejfv. The combination also improved pathological complete response rates, meaning no detectable cancer remained in tissue samples following treatment. Patients receiving the MSD combination achieved: 55.8% pathological complete response rate compared with: 32.5% for chemotherapy plus surgery These results suggest that combining immune checkpoint inhibition with antibody-drug conjugate therapy could provide a more effective treatment approach for some patients with MIBC. Expanding Treatment Options Before and After Surgery Muscle-invasive bladder cancer represents an aggressive form of bladder cancer where tumours have grown into the muscle layer of the bladder wall. Standard treatment has traditionally involved chemotherapy followed by radical cystectomy, a surgical procedure to remove the bladder. However, a significant proportion of patients are unable to receive cisplatin-based chemotherapy due to factors including kidney function, age or other health conditions. The latest FDA approvals expand treatment options by providing a perioperative approach that can be used regardless of cisplatin eligibility. MSD Research Laboratories senior vice-president and global clinical development oncology head Dr Marjorie Green said the approvals represent progress for patients with MIBC. “The results from KEYNOTE-B15, together with KEYNOTE-905, highlight the potential of these new treatment options for patients regardless of cisplatin eligibility in the perioperative setting and mark a promising step forward in the treatment of muscle-invasive bladder cancer,” Green said. Safety Profile of Keytruda and Padcev Combination The FDA approval included safety data from patients treated in the neoadjuvant setting. Permanent discontinuation of pembrolizumab due to adverse reactions occurred in: 17% of patients during the neoadjuvant phase Reported serious adverse reactions included: Rash Pneumonitis or interstitial lung disease Diarrhoea Fatal adverse reactions occurred in: 1.7% of patients during the neoadjuvant phase 3.2% of patients during the adjuvant phase Healthcare providers will continue to monitor patients receiving the combination for immune-related adverse events and complications associated with treatment. Keytruda and Padcev Continue to Expand Across Bladder Cancer The latest approval builds on previous regulatory decisions supporting the use of Keytruda-based combinations in bladder cancer. The FDA decision follows earlier approval activity linked to the Phase III KEYNOTE-905 (EV-303) trial, which also evaluated pembrolizumab and enfortumab vedotin-ejfv in patients with MIBC. Outside the US, the European Commission recently approved MSD’s Keytruda combination with Padcev as a neoadjuvant treatment option for MIBC. The continued expansion of the Keytruda platform highlights the growing importance of combination approaches in oncology, particularly therapies that pair immune checkpoint inhibitors with targeted cancer treatments such as antibody-drug conjugates. What This Means for the Muscle-Invasive Bladder Cancer Market The FDA approvals mark a significant development in the treatment landscape for muscle-invasive bladder cancer by introducing a new perioperative option that could reduce reliance on traditional chemotherapy pathways. For oncologists, the decision provides another treatment strategy for managing MIBC patients before and after surgery. For the pharmaceutical market, the approval reinforces MSD’s position in immuno-oncology while highlighting the increasing role of combination therapies in improving cancer outcomes. As clinical data continues to mature, the long-term impact of Keytruda and Padcev combinations will depend on durability of response, overall survival benefits and adoption across treatment centres. Summary The FDA has approved MSD’s Keytruda and Keytruda Qlex combinations with Padcev for adults with muscle-invasive bladder cancer. The approvals are based on Phase III KEYNOTE-B15 data showing: A 47% reduction in event-free survival risk A 35% reduction in risk of death Higher pathological complete response rates compared with chemotherapy The decision expands treatment options for patients with MIBC regardless of cisplatin eligibility and represents another step forward for combination immunotherapy approaches in oncology. Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com